Long-term kidney outcomes associated with telitacicept in patients with IgA nephropathy: a 24-month retrospective comparative cohort study
Cheng Hanbing, Liu Youxia, Li Hongfen, Wang Fanghao, Xing Yue, Li Wenying, Wu Zhanfei, Zhang Kai, Wang pengzhi, Xu Mengke, Jia Junya · 2026
Read Long-term kidney outcomes associated with telitacicept in patients with IgA nephropathy: a 24-month retrospective comparative cohort study by Cheng Hanbing, Liu Youxia, Li Hongfen, Wang Fanghao, Xing Yue, Li Wenying, Wu Zhanfei, Zhang Kai, Wang pengzhi, Xu Mengke, Jia Junya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13627829.txt.
Description
Cheng Hanbing and ten co-authors report long-term kidney results for a newer drug in IgA nephropathy, in this 2026 research letter. In that disease, faulty antibodies damage the kidney's filters, and steady protein leakage plus falling function lead toward kidney failure. The drug, telitacicept, blocks two signals that keep antibody-making cells alive. Earlier trials showed it cuts protein in the urine, but real-world evidence on kidney function over years was thin.
The team screened 682 patients with biopsy-proven disease at one center. After matching, they compared ten patients treated with the drug against twenty similar patients who were not, following both for twenty-four months. They tracked urine protein and the kidneys' filtering rate over that span. Small matched studies cannot settle a drug's worth, but they show whether trial promise survives contact with routine care.
Catalog record
| CREATOR | Cheng Hanbing, Liu Youxia, Li Hongfen, Wang Fanghao, Xing Yue, Li Wenying, Wu Zhanfei, Zhang Kai, Wang pengzhi, Xu Mengke, Jia Junya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |